The global pharmaceutical company intends to accelerate future launches for medication that address unmet medical needs in the country.


The ribbon cutting ceremony, held on 6 November 2022, at the new Astellas Scientific office in Cairo was officiated by Mr. Leon Moore, President, International Markets Commercial, Astellas (second from the left) and Mr. Katsunobu Takada, Deputy Chief of Mission, Embassy of Japan in Egypt (first on the left).


Cairo, November 6, 2022 - Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a global pharmaceutical company committed to turning innovative science into value for patients, has announced the official inauguration of its newly established Scientific Office in Cairo.

As part of Astellas’ long-term commitment to Egypt, the office in Cairo reiterates the company’s strong belief in deepening its roots within the community. This will enable Astellas to better address unmet medical needs, support the local healthcare infrastructure and accelerate the availability of innovative treatments.

Leon Moore, President of International Markets Commercial, Astellas said: “Building a base in Cairo is a significant milestone for Astellas that will enable us to better serve the needs of patients and the healthcare community. We look forward to working closely with the local authorities and healthcare providers to create sustainable solutions aligned with Egypt’s Vision 2030 and healthcare goals. By enhancing our presence in the country, we are better equipped to ensure the availability of our treatments that bring relief and hope to patients and their families.”

Future products and new indications for medications will be prioritized for launch in the country. This includes select oncology medication targeting disease areas such as Acute Myeloid Leukaemia (AML), Urothelial and Gastric Cancer. In addition to its oncology pipeline the company plans to introduce medication to treat anaemia in patients with chronic kidney disease, as well as technologies in regenerative medicine and gene therapy.

Astellas also plans to scale up local investment through education and training in partnership with key stakeholders, industry partners and healthcare providers. These programs will cover a range of topics from disease awareness to education on medication. This is in line with the government’s goal to enhance the quality of healthcare services in Egypt.


About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.